本帖最后由 老马 于 2012-1-13 21:20 编辑
6 i; r! f2 ~& {; P% s# P3 [
3 M* f# c, o: d) `; P6 p9 H爱必妥和阿瓦斯丁的比较8 l0 v$ x( C! m* Z' ~4 \3 L0 T. \
5 I# \4 @* f; [, H& J- Ghttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! t. B/ e& L$ k. d& Y3 l0 @
# `( f1 g6 Q: A& E# e
2 A7 H2 q ^' H+ k7 ~$ Hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/7 b# a9 j# f* F( `& H
==================================================0 u, G! ^" s/ Q; P& Z, U
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)+ d) k& C, w+ p' a Z3 {6 b" `* s" L
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.: s: L: I( j* y( v! ~9 M
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: g! e7 X+ e* Y {
|